Synthesis and antiplasmodial evaluation of novel mefloquine-based fumardiamides

Open access


The paper is focused on the synthesis and screening of the antiplasmodial activity of novel fumardiamides 5–10 with the mefloquine pharmacophore and a Michael acceptor motif. Multi-step reactions leading to the title compounds included two amide bond formations. The first amide bond was achieved by the reaction of (E)-ethyl 4-chloro-4-oxobut-2-enoate (1) and N 1-(2,8-bis(trifluoromethyl)quinolin-4-yl) butane-1,4-diamine (2). The obtained ester 3 was hydrolyzed and gave acid 4, which then reacted with the selected halogenanilines in the presence of HATU/DIEA and formed products 5–10. Title compounds showed marked, dose dependent activity in vitro against hepatic stages of Plasmodium berghei. IC 50 values of the most active compounds 5, 7 and 9 bearing 3-fluoro, 3-chloro and 3-trifluoromethyl substituents were 3.04–4.16 µmol L−1, respectively. On the other hand, the compounds exerted only weak activity against the erythrocytic stages of two P. falciparum strains (Pf3D7 and PfDd2) in vitro, with the exception of compound 5 (IC 50 = 2.9 µmol L−1).

1. G. Padmanaban and P. N. Rangarajan, Heme metabolism of Plasmodium is a major antimalarial target, Biochem. Biophys. Res. Commun. 268 (2000) 665–668;

2. C. Even, S. Friedman and K. Lamouar, Bipolar disorder after mefloquine treatment, J. Psychiatry Neurosci. 26 (2001) 252–253.

3. F. de Pilla Varotti, A. C. C. Botelho, A. A. Andrade, R. C. de Paula, E. M. S. Fagundes, A. Valverde, L. M. U. Mayer, J. S. Mendonça, M. V. N. de Souza, N. Boechat and A. U. Krettli, Synthesis, antimalarial activity, and intracellular targets of MEFAS, a new hybrid compound derived from mefloquine and artesunate, Antimicrob. Agents Chemother. 52 (2008) 3868–3874;

4. A. R. Hamann, C. de Kock, P. J. Smith, W. A. L. van Otterlo and M. A. L. Blackie, Synthesis of novel triazole-linked mefloquine derivatives: Biological evaluation against Plasmodium falciparum, Bioorg. Med. Chem. Lett. 24 (2014) 5466–5469;

5. N. Sharma, S. Thomas, E. B. Golden, F. M. Hofman, T. C. Chen, N. A. Petasis, A. H. Schönthal and S. G. Louie, Inhibition of autophagy and induction of breast cancer cell death by mefloquine, an antimalarial agent, Cancer Lett. 326 (2012) 143–154;

6. F. A. Rodrigues, I. S. Bomfim, B. C. Cavalcanti, C. Pessoa, R. S. Goncalves, J. L. Wardell, S. M. Wardell and M. V. de Souza, Mefloquine-oxazolidine derivatives: A new class of anticancer agents, Chem. Biol. Drug Des. 83 (2014) 126–131;

7. T. Küster, B. Stadelmann, R. Rufener, C. Risch, J. Müller and A. Hemphill, Oral treatments of Echinococcus multilocularis-infected mice with the antimalarial drug mefloquine that potentially interacts with parasite ferritin and cystatin, Int. J. Antimicrob. Agents 46 (2015) 546–551;

8. L. E. Bermudez, P. Kolonoski, L. E. Seitz, M. Petrofsky, R. Reynolds, M. Wu and L. S. Young, SRI-286, a thiosemicarbazole, in combination with mefloquine and moxifloxacin for treatment of murine Mycobacterium avium complex disease, Antimicrob. Agents Chemother. 48 (2004) 3556–3558;

9. L. Danelishvili, M. Wu, L. S. Young and L. E. Bermudez, Genomic approach to identifying the putative target of and mechanisms of resistance to mefloquine in Mycobacteria, Antimicrob. Agents Chemother. 49 (2005) 3707–3714;

10. R. S. Gonçalves, C. R. Kaiser, M. C. Lourenço, F. A. Bezerra, M. V. de Souza, J. L. Wardell, S. M. Wardell, M. D. Henriques and T. Costa, Mefloquine-oxazolidine derivatives, derived from mefloquine and arenecarbaldehydes: In vitro activity including against the multidrug-resistant tuberculosis strain T113, Bioorg. Med. Chem. 20 (2012) 243–248;

11. J. Mao, H. Yuan, Y. Wang, B. Wan, D. Pak, R. He and S. G. Franzblau, Synthesis and antituberculosis activity of novel mefloquine-isoxazole carboxylic esters as prodrugs, Bioorg. Med. Chem. Lett. 20 (2010) 1263–1268;

12. S. Eswaran, A. V. Adhikari, I. H. Chowdhury, N. K. Pal and K. D. Thomas, New quinoline derivatives: Synthesis and investigation of antibacterial and antituberculosis properties, Eur. J. Med. Chem. 45 (2010) 3374–3383;

13. G. Džimbeg, B. Zorc, M. Kralj, K. Ester, K. Pavelić, J. Balzarini, E. De Clercq and M. Mintas, The novel primaquine derivatives of N-alkyl, cycloalkyl or aryl urea: synthesis, cytostatic and antiviral activity evaluations, Eur. J. Med. Chem. 43 (2008) 1180–1187;

14. M. Šimunović, I. Perković, B. Zorc, K. Ester, M. Kralj, D. Hadjipavlou-Litina and E. Pontiki, Urea and carbamate derivatives of primaquine: synthesis, cytostatic and antioxidant activities, Bioorg. Med. Chem. 17 (2009) 5605–5613;

15. I. Perković, S. Tršinar, J. Žanetić, M. Kralj, I. Martin-Kleiner, J. Balzarini, D. Hadjipavlou-Litina and A. M. Katsori, Novel 1-acyl-4-substituted semicarbazide derivatives of primaquine – synthesis, cytostatic, antiviral and antioxidative studies, J. Enzyme Inhib. Med. Chem. 28 (2013) 601–610;

16. K. Pavić, I. Perković, M. Cindrić, M. Pranjić, I. Martin-Kleiner, M. Kralj, D. Schols, D. Hadjipavlou-Litina, A.-M. Katsori and B. Zorc, Novel semicarbazides and ureas of primaquine with bulky aryl or hydroxyalkyl substituents: Synthesis, cytostatic and antioxidative activity, Eur. J. Med. Chem. 86 (2014) 502–514;

17. I. Perković, M. Antunović, I. Marijanović, K. Pavić, K. Ester, M. Kralj, J. Vlainić, I. Kosalec, D. Schols, D. Hadjipavlou-Litina, E. Pontiki and B. Zorc, Novel urea and bis-urea primaquine derivatives with hydroxyphenyl and halogenphenyl substituents: synthesis and biological evaluation, Eur. J. Med. Chem. 124 (2016) 622–636;

18. K. Pavić, I. Perković, P. Gilja, F. Kozlina, K. Ester, M. Kralj, D. Schols, D. Hadjipavlou-Litina, E. Pontiki and B. Zorc, Design, synthesis and biological evaluation of novel primaquine-cinnamic acid conjugates of amide and acylsemicarbazide type, Molecules 21 (2016) 1629–1653;

19. K. Pavić, I. Perković, Š. Pospíšilová, M. Machado, D. Fontinha, M. Prudêncio, J. Jampilek, A. Coffey, L. Endersen, H. Rimac and B. Zorc, Primaquine hybrids as promising antimycobacterial and antimalarial agents, Eur. J. Med. Chem. 143 (2018) 769–779;

20. J. Vlainić, I. Kosalec, K. Pavić, D. Hadjipavlou-Litina, E. Pontiki and B. Zorc, Insights into biological activity of ureidoamides with primaquine and amino acid moieties, J. Enzyme Inhib. Med. Chem. 33 (2018) 376–382;

21. J. Levatić, K. Pavić, I. Perković, L. Uzelac, K. Ester, M. Kralj, M. Kaiser, M. Rottmann, F. Supek and B. Zorc, Machine learning prioritizes synthesis of primaquine ureidoamides with high antimalarial activity and attenuated cytotoxicity, Eur. J. Med. Chem. 146 (2018) 651–667;

22. M. Beus, Z. Rajić, D. Maysinger, Z. Mlinarić, M. Antunović, I. Marijanović, D. Fontinha, M. Prudêncio, J. Held, S. Olgen and B. Zorc, SAHAquines, novel hybrids based on SAHA and primaquine motifs, as potential anticancer and antiplasmodial agents, ChemistryOpen 7 (2018) 624–638;

23. Z. Rajić, M. Beus, H. Michnova, J. Vlainić, L. Persoons, I. Kosalec, J. Jampilek, D. Schols, T. Keser and B. Zorc, Asymmetric primaquine and halogenaniline fumardiamides as novel biologically active Michael acceptors, Molecules 23 (2018) Article ID 1724 (18 pages);

24. I. Zhang, M. Beus, U. Stochaj, P. U. Le, B. Zorc, Z. Rajić, K. Petrecca and D. Maysinger, Inhibition of glioblastoma cell proliferation, invasion, and mechanism of action of a novel hydroxamic acid hybrid molecule, Cell Death Discov. 4 (2018) Article ID 41;

25. A. M. Mendes, I. S. Albuquerque, M. Machado, J. Pissarra, P. Meireles and M. Prudêncio, Inhibition of Plasmodium liver infection by ivermectin, Antimicrob. Agents Chemother. 61 (2017) e02005-16;

26. J. Held, T. Gebru, M. Kalesse, R. Jansen, K. Gerth, R. Müller and B. Mordmüller, Antimalarial activity of the myxobacterial macrolide chlorotonil A, Antimicrob. Agents Chemother. 58 (2014) 6378–6384;

27. H. Noedl, J. Bronnert, K. Yingyuen, B. Attlmayr, H. Kollaritsch and M. Fukuda, Simple histidinerich protein 2 double-site sandwich enzyme-linked immunosorbent assay for use in malaria drug sensitivity testing, Antimicrob. Agents Chemother. 49 (2005) 3575–3577;

28. R Core Team, 2015, R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria;; last access December 15, 2018

29. E. Borenfreund and J. A. Puerner, A simple quantitative procedure using monolayer cultures for cytotoxicity assays (HTD/NR-90), J. Tissue Culture Method 9 (1985) 7–9;

30. Chemicalize, 2017, ChemAxon Ltd., Budapest, Hungary;; last access November 28, 2018

31. SwissADME Programs, Swiss Institute of Bioinformatics, Lausanne, Switerland;; last access November 28, 2018

Acta Pharmaceutica

The Journal of Croatian Pharmaceutical Society

Journal Information

IMPACT FACTOR 2017: 1.071
5-year IMPACT FACTOR: 1.623

CiteScore 2017: 1.46

SCImago Journal Rank (SJR) 2017: 0.362
Source Normalized Impact per Paper (SNIP) 2017: 0.642


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 177 177 96
PDF Downloads 68 68 31